CEO Clay Siegall (L) and CMO Roger Dansey, Seagen
May 9, 2022 07:05 AM EDTUpdated May 10, 05:08 AM
People
R&D

In wake of do­mes­tic vi­o­lence al­le­ga­tion, long­time Seagen CEO Clay Sie­gall goes on leave

Amber Tong

Clay Sie­gall, the co-founder and long­time CEO of Seagen, is on a leave of ab­sence fol­low­ing an al­leged in­ci­dent of do­mes­tic vi­o­lence, the com­pa­ny re­vealed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times